UNSPSC 51162604: Benproperine

This classification denotes an antitussive agent with the molecular formula C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3AA6IZ48YK, chemically known as piperidine, 1-(1-methyl-2-((alpha-phenyl-o-tolyl)oxy)ethyl)- but more generally known as benproperine, which bears US NIH Compound Identifier 2326. Benproperine most often comes in basem, embonate, pamoate, phosphate, and trihydrogen phosphate forms.

UNSPSC 51162604 Benproperine is a Commodity code that in recent state and local solicitations covers the procurement of naloxone, pharmaceutical products, and over-the-counter medications supplied through authorized wholesalers and direct-purchase arrangements. State and local governments buying under this code include county health departments, state pharmaceutical cooperative purchasing alliances, and participating municipalities within multistate cooperative frameworks. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing-body types currently active in the code's market—county health agencies acquiring specific life-safety pharmaceuticals for community health initiatives, and state procurement offices establishing master agreements with multiple awards to serve participating jurisdictions across multiple states.

Recent activity spans Florida and the Upper Midwest. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Seminole County Community Health Building, Sanford, Florida; the IFB response deadline was July 26, 2023. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon; the RFP response deadline was March 26, 2026, with proposals submitted through the ePro procurement system and pricing evaluated on competitiveness (75 percent weight), fixed pricing (10 percent), compliance with administrative format and EDI capability (5 percent each), and agreement to a 3 percent administrative fee (5 percent). Vendors responding to MMCAP must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, or Morris & Dickson) and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.